LGND up +3.79% percent right now. $LGND High is at
Post# of 64086
Posted On: 11/11/2014 12:53:28 PM
LGND up +3.79% percent right now. $LGND High is at 57.88 and the Low 55.60 with current volume of 171,280.
Recent News posted below.
LGND Ligand Pharmaceuticals Inc Recent Headline News
Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 30 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.05 (+2.37)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.05 (+2.37)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.87 (+0.05), GILD: 108.66 (+1.64), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.16 (-1.71), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)
Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PFE: 30.21 (+0.01), AZN: 74.26 (+1.05), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)
Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT
LGND: 58.05 (+2.37)
Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT
LGND: 58.05 (+2.37)
Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.05 (+2.37)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT
ROP: 157.25 (-1.28), SIR: 24.19 (-0.05), VNDA: 12.80 (+0.64), STX: 61.63 (-0.14), NMM: 13.62 (-0.02), LGND: 58.05 (+2.37), PDS: 7.90 (+0.14), TREX: 43.98 (-0.03), EXAS: 22.61 (+0.01), AWI: 49.18 (+0.01), EDR: 11.55 (-0.07), HUN: 25.02 (+0.09), TEN: 53.21 (-0.23), AGN: 195.91 (+0.67), ONB: 14.86 (-0.05), STNG: 8.77 (+0.13), MRK: 59.55 (+0.74), BEN: 56.83 (+0.26)
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.47 (+0.53), PFE: 30.21 (+0.01), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)
Recent News posted below.
LGND Ligand Pharmaceuticals Inc Recent Headline News
Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 30 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.05 (+2.37)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.05 (+2.37)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.87 (+0.05), GILD: 108.66 (+1.64), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)
Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.16 (-1.71), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)
Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PFE: 30.21 (+0.01), AZN: 74.26 (+1.05), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)
Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT
LGND: 58.05 (+2.37)
Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.05 (+2.37)
Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT
LGND: 58.05 (+2.37)
Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.05 (+2.37)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT
ROP: 157.25 (-1.28), SIR: 24.19 (-0.05), VNDA: 12.80 (+0.64), STX: 61.63 (-0.14), NMM: 13.62 (-0.02), LGND: 58.05 (+2.37), PDS: 7.90 (+0.14), TREX: 43.98 (-0.03), EXAS: 22.61 (+0.01), AWI: 49.18 (+0.01), EDR: 11.55 (-0.07), HUN: 25.02 (+0.09), TEN: 53.21 (-0.23), AGN: 195.91 (+0.67), ONB: 14.86 (-0.05), STNG: 8.77 (+0.13), MRK: 59.55 (+0.74), BEN: 56.83 (+0.26)
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.47 (+0.53), PFE: 30.21 (+0.01), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)
(0)
(0)Scroll down for more posts ▼